Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system? (Q27022015)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25848475%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

review article

1 reference

title

Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25848475%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

main subject

hepatocellular carcinoma

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25848475%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

author name string

Xavier Adhoute

1

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25848475%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Paul Castellani

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25848475%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Herve Perrier

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25848475%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Marc Bourliere

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25848475%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

language of work or name

1 reference

1 March 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25848475%20AND%20SRC:MED&resulttype=core&format=json

World Journal of Hepatology

4 March 2020

published in

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25848475%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

volume

7

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25848475%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

issue

3

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25848475%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

page(s)

521-531

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25848475%20AND%20SRC:MED&resulttype=core&format=json

Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma

4 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

21 March 2017

Hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

7 April 2017

Hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Risk factors and therapeutic results of early local recurrence after transcatheter arterial chemoembolization

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: analyzing patterns of progression in 285 patients.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

The challenge of prognosis and staging for hepatocellular carcinoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

International trends in liver cancer incidence rates

31 May 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I3.521

Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I3.521

Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I3.521

Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I3.521

Cochrane Database of Systematic Reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I3.521

Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I3.521

Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402).

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I3.521

Selective and sequential transarterial chemoembolization: survival in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I3.521

Complications associated with transcatheter arterial embolization for hepatic tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I3.521

The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I3.521

Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I3.521

Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I3.521

Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I3.521

The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I3.521

Assessment for retreatment (ART) score for repeated transarterial chemoembolization in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I3.521

Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demand"

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I3.521

Unresectable hepatocellular carcinoma: survival and prognostic factors after lipiodol chemoembolisation in 89 patients.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4381174

Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization

28 November 2018

1 reference

12 December 2020

A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization

1 reference

12 December 2020

Usefulness of the HKLC vs. the BCLC staging system in a European HCC cohort

1 reference

12 December 2020

Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study

1 reference

12 December 2020

EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization

1 reference

12 December 2020

Identifiers

DOI

10.4254/WJH.V7.I3.521

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25848475%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25848475%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25848475%20AND%20SRC:MED&resulttype=core&format=json